Page 132 - 2018_11-Haematologica-web

K. Seipel et al.
therapeutic target identified by gene
expression based classification. Cancer
Cell. 2003;3(2):173-183.
31. Stam RW, den Boer ML, Schneider P, et al.
Targeting FLT3 in primary MLL-gene- rearranged infant acute lymphoblastic leukemia. Blood. 2005;106(7):2484-2490.
32. Wattel E, Preudhomme C, Hecquet B, et al. p53 mutations are associated with resist- ance to chemotherapy and short survival in hematologic malignancies. Blood. 1994; 84(9):3148-3157.
33. Long J, Parkin B, Ouillette P, et al. Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia. Blood. 2010;116(1):71-80.
34. Muller PAJ, Vousden KH. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell. 2014; 25(3):304- 317.
35. Zauli G, Celeghini C, Melloni E, et al. The
sorafenib plus nutlin-3 combination pro- motes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status. Haematologica. 2012; 97(11):1722-1730.
36. Grisendi S, Mecucci C, Falini B, Pandolfi PP. Nucleophosmin and cancer. Nat Rev Cancer. 2006;6(7):493-505.
37. Colombo E, Marine J-C, Danovi D, Falini B, Pelicci PG. Nucleophosmin regulates the stability and transcriptional activity of p53. Nat Cell Biol. 2002;4(7):529-533.
38. Schlenk RF, Döhner K, Krauter J, et al. Mutations and treatment outcome in cyto- genetically normal acute myeloid leukemia. N Engl J Med. 2008;358(18):1909-1918.
39. Sperr WR, Zach O, Pöll I, et al. Karyotype plus NPM1 mutation status defines a group of elderly patients with AML (≥60 years) who benefit from intensive post-induction consolidation therapy. Am J Hematol. 2016;91(12):1239-1245.
40. Stone RM, Mandrekar S, Sanford BL, et al. The multi-kinase inhibitor midostaurin (M) prolongs survival compared with placebo (P) in combination with daunorubicin (D)/cytarabine (C) induction (ind), high- dose C consolidation (consol), and as main- tenance (maint) therapy in newly diag- nosed acute myeloid leukemia (AML) patients (pts) age 18-60 with FLT3 muta- tions (muts): an international prospective randomized (rand) P-controlled double- blind trial (CALGB 10603/RATIFY [Alliance]). Blood. 2015;126(23):6-6.
41. Starr P. Midostaurin the first targeted thera- py to improve survival in AML: potentially practice-changing. Am Health Drug Benefits. 2016;9(Spec Issue):1-21.
42. Chou T-C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010; 70(2):440-446.
1872
haematologica | 2018; 103(11)